Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of antigens from multiple bacterial species
Reexamination Certificate
2001-04-16
2003-12-23
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of antigens from multiple bacterial species
C424S184100, C424S234100, C424S236100, C435S004000, C435S007320
Reexamination Certificate
active
06667040
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions useful for the treatment and prevention of footrot and, in particular, bovine footrot.
BACKGROUND OF THE INVENTION
Acute bovine footrot, also known as interdigital phlegmon or acute interdigital phlegmon (AIP), is a common infection in cattle [1,11]. The actual prevalence of this disease in many types of cattle is not fully described; however, in some years the prevalence in feedlot animals can reach 10-25% if preventative measures such as feeding antibiotics are not widely implemented.
It is an anaerobic bacterial infection characterized by acute inflammation which is manifested as tissue edema and local infiltration of subcutaneous tissues with polymorphonuclear granulocytic neutrophils (PMN) [16]. Typically this disease involves necrosis of the interdigital epidermis and the underlying dermis. Very often there is an ascending cellulitis which can result in severe swelling from the coronet to the fetlock joint. This infection, if left untreated, can result in sequelae such as septic joint involvement which can lead to euthanasia [2].
The infection is thought to be caused by a synergistic association of anaerobic bacteria including
Bacteroides melaninogenicus, Fusobacterium necrophorum [
12], and possibly other bacteria such as
Dichelobacter
(
Bacteroides
)
nodosus [
13] or
Actinomyces pyogenes [
14]. Recently
B.melaninogenicus
has been divided into several distinct species of bacteria including Porphyromonas sp and Prevotella sp [4].
Fusobacterium necrophorum
and
B. melaninogenicus
have been previously used together to experimentally infect cattle [12]. That investigation did not examine microscopic pathology or the minimum inhibitory concentrations [MIC's] and minimum bactericidal concentrations [MBC's] of the antibiotic(s) for the pathogens used in the experimental infection.
Several treatments have been advocated for acute bovine footrot including penicillin [11], oxytetracycline [15], cephalosporins [16], and sulfonamides [11].
Parenteral antibiotic treatment of individual clinically affected animals is effective for treating cattle that can be easily handled and frequently observed. Therapy in fat cattle (i.e., animals nearly ready for marketing as beef) is complicated by the fact that many of these drugs cannot be used without delaying slaughter. Antibiotics without withdrawal periods are available for these animals; however, the expense remains significant. Currently, recommended therapy for these animals can involve daily treatment for up to five days or longer. Cephalosporin, a &bgr;-lactam antibiotic, is one recommended therapeutic regimen. For a 500 kg steer, cephalosporin therapy for five days can approach $50 in antibiotic cost alone for a single episode of the disease. This clearly does not include the costs of manpower for giving the treatments, the costs of lost production (e.g., reduced weight gain) in affected cattle, or the significant animal suffering that occurs as a result of this infectious lameness.
There are potentially devastating effects of this disease in breeding bulls if the infection occurs during breeding season and libido is reduced. Conventional antibiotic therapy in mature breeding bulls is problematic because of the frequency of treatments and the massive volume of antibiotic required, in addition to the cost of antibiotics. Although infection can be minimized in some types of cattle through feeding antibiotics, fat cattle are again at high risk because of our inability to use these drugs due to withdrawal times. Preventative measures, such as footbaths, are recommended in many parts of the world but are not practical under many circumstances. The potential environmental implications of using compounds such as blue stone and formaldehyde are also a consideration.
Animals affected with AIP are believed to develop immunity, but the importance of this immunity is unclear [2]. In many acute infectious inflammatory diseases phagocytosis by polymorphonuclear granulocytic neutrophils (PMN) is a central mechanism in the resolution of infection, but these cells have never been specifically evaluated in the context of acute bovine footrot. Specific immunity to etiologic agents of footrot also may be important in resolution of the infection [2]; however, studies have yet to be conducted on precisely how these cells are involved in the mechanisms of this process.
The development of a therapeutic agent and/or a vaccine, additional tools for cattlemen to minimize the effects of footrot, would be worthwhile and a significant contribution to sustainable agricultural practices.
Traditionally,
Fusobacterium necrophorum
has been described as the cause of bovine footrot [2-4]. Vaccines based on this microorganism are known and/or available [5,8,9], but efficacy is questionable and use is not broad. Use of 6-substituted 3-nitroimidazo[1,2,b]pyridazine for the control of footrot and liver lesions caused by
Fusobacterium necrophorum
has also been disclosed [10].
SUMMARY OF THE INVENTION
This invention provides a method of preventing or treating bovine footrot by administering vaccine compositions comprising at least one of the causative agents of bovine footrot, i.e., Porphyromonas and Prevotella and/or subunits and/or toxins thereof. Compositions comprising
Porphyromonas levii
and
Prevotella intermedia
are preferred. Protectively immunogenic vaccine compositions may also contain a specific bovine immunoglobulin G
2
(IgG
2
) destroying toxin of
Porphyromonas levii
and a &bgr;-lactamase enzyme of
Prevotella intermedia,
either or both of which can be inactivated and included in the vaccine composition. The invention also provides a method of treating or preventing bovine footrot by administering compositions comprising at least one neutralizing agent, e.g., an antibody, to a causative agent of bovine footrot, i.e., Porphyromonas and Prevotella and/or subunits and/or toxins thereof. Compositions comprising antibodies to
Porphyromonas levii
and
Prevotella intermedia
and/or their toxin(s) or subunit(s) are preferred. Effective compositions may contain antibodies to immunoglobulin proteases, including a specific bovine immunoglobulin G
2
(IgG
2
) destroying toxin of
Porphyromonas levii
and/or antibodies to antibiotic resistance enzymes, including a &bgr;-lactamase enzyme of
Prevotella intermedia.
Our isolation techniques and our immunology studies suggest that Porphyromonas (and especially
P. levii
) and Prevotella (and especially
P. intermedia
) are more appropriate vaccine candidates than
Fusobacterium necrophorum.
Using surgical biopsy techniques and stringent anaerobic culture methodology, we have not isolated
Fusobacterium necrophorum
from internal infected tissues in a single case of bovine footrot.
The invention provides compositions and methods for preventing or treating infectious lameness, particularly in cattle, using the bacteria Porphyromonas and/or Prevotella, toxins isolated from these bacteria, and neutralizing agents which may be used in the compositions. The invention provides methods of preparing and methods of using a bacterial protease toxin, an antibiotic destroying toxin, and antibodies to the toxins.
Accordingly, in one aspect, the invention provides compositions for preventing or treating footrot comprising Porphyromonas and/or Prevotella. Compositions comprising subunit(s) and/or toxin(s) of these bacteria are also provided, as are methods of preparing these compositions.
A further aspect of the invention is a method of preventing or treating infection in an animal comprising administering to the animal an effective amount of a composition comprising Porphyromonas and/or Prevotella and/or subunit(s) and/or toxin(s) thereof.
Another aspect of the invention provides isolated toxins from Porphyromonas and/or Prevotella. Methods of p
Morck Douglas W.
Olson Merle E.
Burns Doane , Swecker, Mathis LLP
Ford Vanessa L
Smith Lynette R. F.
University Technologies International Inc.
LandOfFree
Bovine footrot treatment and prevention does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bovine footrot treatment and prevention, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bovine footrot treatment and prevention will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3175129